Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

Topline data were announced from a phase 3 trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...

Mineralys Therapeutics (Nasdaq: MLYS) saw its stock rise by over 40% after reporting positive top-line results from two ...

Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Mineralys Therapeutics, Inc. announced positive topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials, evaluating the efficacy and safety of lorundrostat in treating ...

Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.

Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...